Randomized Trial Highlights Ketogenic Diet Benefits in Psychotic Disorders
A new clinical study published in Schizophrenia Bulletin has provided encouraging evidence that a ketogenic diet may offer meaningful benefits for individuals living with serious mental illnesses such as schizophrenia-spectrum disorders and bipolar I disorder. Conducted by researchers at the University of California, San Francisco (UCSF) and supported in part by the National Institute of Mental Health (NIMH), the investigation represents one of the first randomized controlled trials (RCTs) to systematically evaluate ketogenic therapy as a potential intervention for psychotic disorders.
The findings suggest that the high-fat, very low-carbohydrate dietary approach not only improves important metabolic health indicators but may also contribute to reductions in psychiatric symptoms and enhancements in cognitive function when maintained over several months.
Although the researchers caution that larger and longer-term studies are still needed before ketogenic therapy can become part of routine psychiatric care, the trial adds to a growing body of evidence supporting the connection between metabolism and mental health.
Exploring a New Approach to Psychiatric Care
Serious mental illnesses such as schizophrenia and bipolar I disorder affect millions of people worldwide and are often associated with lifelong disability. While modern antipsychotic medications can effectively reduce hallucinations, delusions, and mood instability, many patients continue to struggle with persistent cognitive impairment, depression, reduced motivation, and poor overall quality of life.
In addition, many psychiatric medications contribute to weight gain, insulin resistance, diabetes, and cardiovascular disease, creating additional long-term health challenges.
Researchers have increasingly explored whether improving metabolic function might also improve brain function.
The ketogenic diet has attracted considerable scientific interest because it shifts the body’s primary energy source from glucose to ketone bodies, produced during the metabolism of dietary fats. This metabolic state, known as ketosis, has long been used to treat drug-resistant epilepsy and has more recently been investigated for neurological disorders, neurodegenerative diseases, and psychiatric conditions.
The UCSF study sought to determine whether inducing nutritional ketosis could positively influence both physical and mental health in individuals with psychotic disorders.
Randomized Controlled Trial Design
The clinical investigation enrolled 58 adults diagnosed with either schizophrenia-spectrum disorders or bipolar I disorder.
Participants were randomly assigned to one of two groups during an initial one-month study period:
- A ketogenic diet intervention group
- A diet-as-usual control group
Of the original participants, 47 individuals completed the randomized controlled portion of the trial.
Following completion of the first month, participants receiving ketogenic therapy were offered the opportunity to continue the dietary intervention through an additional four-month extension phase.
Twenty-five participants chose to remain on the ketogenic diet for the extended observation period, allowing researchers to evaluate longer-term effects on metabolic, psychiatric, and cognitive outcomes.
Although the extension phase was conducted as a single-arm study without a control group, it provided valuable information regarding the sustainability of dietary adherence and potential long-term therapeutic benefits.
High Adherence Demonstrates Feasibility
One of the study’s most notable findings involved participant adherence to the ketogenic diet.
Maintaining nutritional ketosis can be challenging because it requires substantial reductions in carbohydrate intake while increasing dietary fat consumption.
Researchers monitored ketosis using daily ketone testing throughout the study.
The results demonstrated remarkably high compliance:
- 83% of participants maintained ketosis during the initial randomized controlled phase.
- 94% successfully maintained ketosis throughout the four-month extension.
Importantly, investigators reported no significant side effects associated with the dietary intervention.
These findings suggest that, with appropriate guidance and monitoring, ketogenic therapy may be both practical and well tolerated among individuals living with serious psychiatric disorders.
Significant Improvements in Metabolic Health
After just one month, participants assigned to the ketogenic diet experienced statistically significant improvements in several important metabolic measurements compared with those who continued their usual diets.
Among the most notable findings were reductions in blood glucose levels, indicating improved glucose regulation.
The researchers also discovered an important relationship between ketone production and mental health outcomes.
Higher ketone levels were associated with:
- Lower blood glucose concentrations
- Reduced symptoms of depression measured using the Patient Health Questionnaire-9 (PHQ-9)
Importantly, these associations remained statistically significant even after researchers adjusted for weight loss.
This observation suggests that ketosis itself—not simply losing weight—may contribute to improvements in both metabolism and mood.
The finding strengthens the hypothesis that changes in brain energy metabolism could influence psychiatric symptoms independently of body weight.
Longer-Term Benefits Extend Beyond Metabolism
While metabolic improvements became evident during the initial month of treatment, the study found that longer-term ketogenic therapy produced broader health benefits.
Participants who continued the dietary intervention for four months demonstrated sustained improvements in metabolic health alongside significant psychiatric and cognitive gains.
Researchers observed reductions in:
- Depression symptoms
- Schizophrenia-related symptoms
- Overall psychiatric burden
In addition to improvements in emotional wellbeing, participants also showed measurable enhancements in cognitive performance.
These cognitive gains are particularly significant because impairments in memory, attention, executive function, and information processing are among the most disabling aspects of schizophrenia-spectrum disorders and bipolar illness.
Unlike hallucinations or mood episodes, cognitive dysfunction often persists even when psychiatric symptoms are well controlled with medication.
Currently available pharmacological treatments offer limited benefit for these cognitive deficits.
Addressing an Important Treatment Gap
The study’s lead investigator, Dr. Judith M. Ford, Professor of Psychiatry at UCSF and a researcher at the Weill Institute for Neurosciences, emphasized the importance of the cognitive findings.
She noted that although existing medications can effectively manage psychotic symptoms, they generally do not address many aspects of patients’ broader mental wellbeing.
Persistent depression, impaired thinking, reduced concentration, and cognitive dysfunction frequently interfere with employment, education, social relationships, and independent living.
According to Dr. Ford, improvements observed in these areas during the study highlight the potential value of exploring metabolic therapies as complementary treatments alongside standard psychiatric medications.
At the same time, she stressed that larger, fully controlled clinical trials will be necessary to determine whether these encouraging findings can be consistently reproduced across broader patient populations.
Why Ketosis May Influence Brain Function
Although the exact biological mechanisms remain under investigation, several scientific theories may explain how ketogenic therapy influences psychiatric symptoms.
Ketones provide an alternative energy source for neurons, potentially improving mitochondrial function and reducing energy deficits within the brain.
Researchers also believe ketosis may:
- Reduce oxidative stress
- Improve mitochondrial efficiency
- Enhance neurotransmitter balance
- Decrease inflammation
- Improve insulin sensitivity
- Support healthier brain metabolism
Many scientists increasingly recognize that metabolic dysfunction and psychiatric illness may share common biological pathways.
Emerging evidence suggests that insulin resistance, impaired glucose metabolism, mitochondrial dysfunction, and chronic inflammation may contribute to the development or worsening of several psychiatric disorders.
By addressing these underlying metabolic abnormalities, ketogenic therapy may positively influence brain function in ways that extend beyond symptom control alone.
Need for Larger Clinical Trials
Despite the encouraging findings, the researchers caution against drawing definitive conclusions based on the current study.
The randomized controlled portion lasted only one month, which the authors believe may be too short to fully capture the therapy’s psychiatric benefits.
The more substantial improvements in cognition and psychiatric symptoms emerged during the four-month extension.
However, because the extension lacked a randomized control group, additional controlled studies will be necessary to confirm whether these improvements were directly attributable to ketogenic therapy.
Future research will need to evaluate:
- Larger patient populations
- Longer treatment durations
- Diverse psychiatric diagnoses
- Long-term safety
- Sustainability of dietary adherence
- Comparative effectiveness alongside standard treatments
The investigators believe such studies are essential before ketogenic therapy can be widely recommended within psychiatric practice.
Growing Interest in Metabolic Psychiatry
The findings align with several recent pilot studies investigating ketogenic therapy in schizophrenia and bipolar disorder.
Together, these studies contribute to the rapidly expanding field of metabolic psychiatry, an emerging discipline that explores how metabolism influences mental health and how metabolic interventions may complement conventional psychiatric treatments.
Rather than focusing exclusively on neurotransmitters, metabolic psychiatry examines the complex relationships between energy metabolism, inflammation, mitochondrial function, nutrition, and brain health.
This broader perspective may eventually lead to new therapeutic strategies capable of addressing both the psychiatric and physical health challenges faced by individuals living with serious mental illness.
Expanding Scientific Investment
Among the organizations supporting the research was the Baszucki Group, which has become a leading advocate for advancing metabolic psychiatry research.
Jan Ellison Baszucki, co-founder and president of the organization, described the study as further evidence that ketogenic therapy represents a feasible, safe, and potentially transformative approach for treating serious mental illness.
She emphasized that continued investment in rigorous scientific research will be critical for determining the true therapeutic potential of metabolic interventions.
According to Baszucki, expanding clinical studies while increasing awareness among healthcare professionals and patients could help accelerate progress in developing new treatment options that extend beyond traditional pharmacological approaches.
The UCSF randomized controlled trial provides important new evidence supporting the potential role of ketogenic therapy as a complementary treatment for schizophrenia-spectrum disorders and bipolar I disorder.
Participants experienced rapid improvements in metabolic health during the initial month of treatment, while those who maintained the diet for four months demonstrated additional gains in psychiatric symptoms and cognitive function.
Although further large-scale randomized controlled trials are needed to establish efficacy, long-term safety, and optimal implementation strategies, the study represents an important step toward understanding how nutritional interventions may influence serious mental illness.
As research in metabolic psychiatry continues to evolve, ketogenic therapy may eventually emerge as part of a broader, personalized treatment strategy that combines medication, lifestyle interventions, and metabolic optimization to improve both physical and mental health outcomes for individuals living with severe psychiatric disorders.
About Baszucki Group
Launched in 2021 by Roblox founder and Chief Executive Officer David Baszucki and best-selling author Jan Ellison Baszucki, Baszucki Group leverages grantmaking, impact investing, advocacy, storytelling, and community building to drive foundational change in science, medicine, farming, food, and environmental ecosystems. A primary focus of Baszucki Group is supporting initiatives at the intersection of metabolism, psychiatry, and neuroscience with the goal of improving mental health outcomes. To learn more about metabolic approaches to mental disorders and brain health, including ketogenic therapy, visit Metabolic Mind, a nonprofit initiative of Baszucki Group.